Rifampicin treatment greatly increases the apparent oral clearance of quinidine.
We investigated the effect of cytochrome P450 induction by rifampicin on the in vivo oxidative metabolism of quinidine. The pharmacokinetics of a 200 mg oral single dose quinidine were studied before and after one week of daily treatment with 600 mg rifampicin in six healthy young male volunteers. Biomarker reactions of cytochrome P450 isozyme activities in the form of caffeine, sparteine, mephenytoin, tolbutamide and cortisol metabolism were applied. The median total apparent oral clearance and partial clearance by 3-hydroxylation of quinidine increased 9 times. The partial clearance by N-oxidation increased 6 times. The Cmax and the elimination half life were reduced 3 times. No statistically significant changes were found for quinidine tmax and renal clearance. The cortisol metabolic ratio increased 5 times, while no statistically significant effects were seen for other CYP marker reactions. The results indicate that the inductive effect of rifampicin is likely to be of clinical relevance particularly when used concomitantly with drugs metabolized by CYP3A4.
Damkier
P
P
Institute of Public Health, Clinical Pharmacology, University of Southern Denmark, Odense University, Denmark. p-damkier@cek-fo.sdu.dk
Hansen
L L
LL
Brøsen
K
K
D000284:Administration, Oral; D000328:Adult; D000904:Antibiotics, Antitubercular / Q000008:administration & dosage*; D019540:Area Under Curve; D003577:Cytochrome P-450 Enzyme System / Q000096:biosynthesis / Q000378:metabolism; D004790:Enzyme Induction; D006207:Half-Life; D006801:Humans; D008297:Male; D011802:Quinidine / Q000008:administration & dosage / Q000493:pharmacokinetics*; D012016:Reference Values; D012293:Rifampin / Q000008:administration & dosage*
D000904:Antibiotics, Antitubercular; D003577:Cytochrome P-450 Enzyme System; D011802:Quinidine; D012293:Rifampin